Cited by 46Pancreatic and Hepatic Oncology ResearchCancer Cells and MetastasisPancreatic function and diabetes

Isolation of pancreatic cancer cells from a patient-derived xenograft model allows for practical expansion and preserved heterogeneity in culture

Open access
Pham, Kien, Delitto, Daniel, Knowlton, Andrea E., Hartlage, Emily R., Madhavan, Ricky, Gonzalo, David H., Thomas, Ryan M., Behrns, Kevin E. +5 more·2016·The American Journal of Pathology

Abstract

Commercially available, highly passaged pancreatic cancer (PC) cell lines are of limited translational value. Attempts to overcome this limitation have primarily consisted of cancer cell isolation and culture directly from human PC specimens. However, these techniques are associated with exceedingly low success rates. Here, we demonstrate a highly reproducible culture of primary PC cell lines (PPCLs) from patient-derived xenografts, which preserve, in part, the intratumoral heterogeneity known to exist in PC. PPCL expansion from patient-derived xenografts was successful in 100% of attempts (5 of 5). Phenotypic analysis was evaluated with flow cytometry, immunofluorescence microscopy, and short tandem repeat profiling. Importantly, tumorigenicity of PPCLs expanded from patient-derived xenografts was assessed by subcutaneous injection into nonobese diabeteic.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ mice. Morphologically, subcutaneous injection of all PPCLs into mice yielded tumors with similar characteristics to the parent xenograft. PPCLs uniformly expressed class I human leukocyte antigen, epithelial cell adhesion molecule, and cytokeratin-19. Heterogeneity within each PPCL persisted in culture for the frequency of cells expressing the cancer stem cell markers CD44, CD133, and c-Met and the immunologic markers human leukocyte antigen class II and programmed death ligand 1. This work therefore presents a reliable method for the rapid expansion of primary human PC cells and, thereby, provides a platform for translational investigation and, importantly, potential personalized therapeutic approaches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajpath.2016.02.009

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Immortalized cell lines typically retain similarity to their progenitors in culture, including some level of clonal heterogeneity, but they develop genetic instability and frequent aneuploidy.

    “Immortalized cell lines typically retain similarity to their progenitors in culture, including some level of clonal heterogeneity, but they develop genetic instability and frequent aneuploidy [25][26][27].”

    From The history, landscape, and outlook of human cell line authentication and security (2024) · cites this paper as [26]

    The Discussion (page unavailable) contrasts the heterogeneity retained by the authors’ primary pancreatic cancer cultures with the homogeneous populations that can arise after long periods in culture. It also reports a phenotypic departure in established, highly passaged cell lines, contrary to the claim that such lines typically retain similarity and heterogeneity. The paper does not address frequent aneuploidy. (LLM, conf=0.78)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. [1]1. Rahib, L. ∙ Smith, B.D. ∙ Aizenberg, R. ... Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res. 2014; 74:2913-2921 Crossref Scopus (5220) PubMed Google Scholar
  2. [4]4. Baxter, N.N. ∙ Whitson, B.A. ∙ Tuttle, T.M. Trends in the treatment and outcome of pancreatic cancer in the United States Ann Surg Oncol. 2007; 14:1320-1326 Crossref Scopus (127) PubMed Google Scholar
  3. [5]5. Yunis, A.A. ∙ Arimura, G.K. ∙ Russin, D.J. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase Int J Cancer. 1977; 19:128-135 Crossref Scopus (298) PubMed Google Scholar
  4. [6]6. McIntosh, J.C. ∙ Schoumacher, R.A. ∙ Tiller, R.E. Pancreatic adenocarcinoma in a patient with cystic fibrosis Am J Med. 1988; 85:592 Full Text (PDF) Scopus (50) PubMed Google Scholar
  5. [7]7. Lieber, M. ∙ Mazzetta, J. ∙ Nelson-Rees, W. ... Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas Int J Cancer. 1975; 15:741-747 Crossref Scopus (452) PubMed Google Scholar
  6. [8]8. Tan, M.H. ∙ Nowak, N.J. ∙ Loor, R. ... Characterization of a new primary human pancreatic tumor line Cancer Invest. 1986; 4:15-23 Crossref Scopus (193) PubMed Google Scholar
  7. [9]9. Johnson, J.I. ∙ Decker, S. ∙ Zaharevitz, D. ... Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials Br J Cancer. 2001; 84:1424-1431 Crossref Scopus (735) PubMed Google Scholar
  8. [10]10. Daniel, V.C. ∙ Marchionni, L. ∙ Hierman, J.S. ... A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro Cancer Res. 2009; 69:3364-3373 Crossref Scopus (384) PubMed Google Scholar
  9. [11]11. Cassidy, J.W. ∙ Caldas, C. ∙ Bruna, A. Maintaining tumor heterogeneity in patient-derived tumor xenografts Cancer Res. 2015; 75:2963-2968 Crossref Scopus (265) PubMed Google Scholar
  10. [12]12. Ruckert, F. ∙ Aust, D. ∙ Bohme, I. ... Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method J Surg Res. 2012; 172:29-39 Full Text Full Text (PDF) Scopus (55) PubMed Google Scholar
  11. [13]13. Holloway, S. ∙ Davis, M. ∙ Jaber, R. ... A clinically relevant model of human pancreatic adenocarcinoma identifies patterns of metastasis associated with alterations of the TGF-beta/Smad4 signaling pathway Int J Gastrointest Cancer. 2003; 33:61-69 Crossref Google Scholar
  12. [14]14. Chifenti, B. ∙ Morelli, M. ∙ Zavaglia, M. ... Establishment and characterization of 4 new human pancreatic cancer cell lines: evidences of different tumor phenotypes Pancreas. 2009; 38:184-196 Crossref Scopus (14) Google Scholar
  13. [15]15. Kyriazis, A.P. ∙ McCombs, 3rd, W.B. ∙ Sandberg, A.A. ... Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse Cancer Res. 1983; 43:4393-4401 PubMed Google Scholar
  14. [16]16. Kato, M. ∙ Shimada, Y. ∙ Tanaka, H. ... Characterization of six cell lines established from human pancreatic adenocarcinomas Cancer. 1999; 85:832-840 Crossref Scopus (27) PubMed Google Scholar
  15. [17]17. Tentler, J.J. ∙ Tan, A.C. ∙ Weekes, C.D. ... Patient-derived tumour xenografts as models for oncology drug development Nat Rev Clin Oncol. 2012; 9:338-350 Crossref Scopus (1027) PubMed Google Scholar
  16. [18]18. Dangles-Marie, V. ∙ Pocard, M. ∙ Richon, S. ... Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features Cancer Res. 2007; 67:398-407 Crossref Scopus (154) PubMed Google Scholar
  17. [19]19. DeRose, Y.S. ∙ Wang, G. ∙ Lin, Y.C. ... Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes Nat Med. 2011; 17:1514-1520 Crossref Scopus (781) PubMed Google Scholar
  18. [20]20. Martinez-Garcia, R. ∙ Juan, D. ∙ Rausell, A. ... Transcriptional dissection of pancreatic tumors engrafted in mice Genome Med. 2014; 6:27 Crossref Scopus (37) PubMed Google Scholar
  19. [21]21. Delitto, D. ∙ Pham, K. ∙ Vlada, A.C. ... Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements Am J Pathol. 2015; 185:1297-1303 Full Text Full Text (PDF) Scopus (90) PubMed Google Scholar
  20. [22]22. Erkan, M. ∙ Michalski, C.W. ∙ Rieder, S. ... The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma Clin Gastroenterol Hepatol. 2008; 6:1155-1161 Full Text Full Text (PDF) Scopus (337) PubMed Google Scholar
  21. [23]23. Mehrara, E. ∙ Forssell-Aronsson, E. ∙ Ahlman, H. ... Specific growth rate versus doubling time for quantitative characterization of tumor growth rate Cancer Res. 2007; 67:3970-3975 Crossref Scopus (187) PubMed Google Scholar
  22. [24]24. de Sousa Cavalcante, L. ∙ Monteiro, G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer Eur J Pharmacol. 2014; 741:8-16 Crossref Scopus (408) PubMed Google Scholar
  23. [25]25. Li, C. ∙ Heidt, D.G. ∙ Dalerba, P. ... Identification of pancreatic cancer stem cells Cancer Res. 2007; 67:1030-1037 Crossref Scopus (2894) PubMed Google Scholar
  24. [26]26. Li, C. ∙ Wu, J.J. ∙ Hynes, M. ... c-Met is a marker of pancreatic cancer stem cells and therapeutic target Gastroenterology. 2011; 141:2218-2227.e5 Full Text Full Text (PDF) Scopus (310) PubMed Google Scholar
  25. [27]27. Delitto, D. ∙ Perez, C. ∙ Han, S. ... Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer Cancer Immunol Immunother. 2015; 64:1553-1563 Crossref Scopus (25) Google Scholar
  26. [28]28. Sharma, P. ∙ Allison, J.P. The future of immune checkpoint therapy Science. 2015; 348:56-61 Crossref Scopus (3636) PubMed Google Scholar
  27. [30]30. Motzer, R.J. ∙ Rini, B.I. ∙ McDermott, D.F. ... Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial J Clin Oncol. 2015; 33:1430-1437 Crossref Scopus (914) PubMed Google Scholar
  28. [31]31. Le, D.T. ∙ Uram, J.N. ∙ Wang, H. ... PD-1 blockade in tumors with mismatch-repair deficiency N Engl J Med. 2015; 372:2509-2520 Crossref Scopus (7340) PubMed Google Scholar
  29. [32]32. Roberts, Jr., T.G. ∙ Goulart, B.H. ∙ Squitieri, L. ... Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials JAMA. 2004; 292:2130-2140 Crossref Scopus (269) PubMed Google Scholar
  30. [33]33. Thomas, R.M. ∙ Truty, M.J. ∙ Kim, M. ... The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma Ann Surg Oncol. 2015; 22:1884-1892 Crossref Scopus (25) PubMed Google Scholar
  31. [34]34. Kang, Y. ∙ Zhang, R. ∙ Suzuki, R. ... Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype Lab Invest. 2015; 95:207-222 Crossref Scopus (41) Google Scholar
  32. [35]35. Li, C. ∙ Lee, C.J. ∙ Simeone, D.M. Identification of human pancreatic cancer stem cells Methods Mol Biol. 2009; 568:161-173 Crossref Scopus (188) PubMed Google Scholar
  33. [36]36. Li, L. ∙ Hao, X. ∙ Qin, J. ... Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice Gastroenterology. 2014; 146:1108-1118 Full Text Full Text (PDF) Scopus (123) PubMed Google Scholar
  34. [37]37. Abel, E.V. ∙ Simeone, D.M. Biology and clinical applications of pancreatic cancer stem cells Gastroenterology. 2013; 144:1241-1248 Full Text Full Text (PDF) Scopus (89) PubMed Google Scholar
  35. [38]38. Fan, F. ∙ Bellister, S. ∙ Lu, J. ... The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells Br J Cancer. 2015; 112:539-546 Crossref Scopus (29) Google Scholar
  36. [39]39. Garraway, L.A. Genomics-driven oncology: framework for an emerging paradigm J Clin Oncol. 2013; 31:1806-1814 Crossref Scopus (280) PubMed Google Scholar
  37. [40]40. Stebbing, J. ∙ Paz, K. ∙ Schwartz, G.K. ... Patient-derived xenografts for individualized care in advanced sarcoma Cancer. 2014; 120:2006-2015 Crossref Scopus (139) PubMed Google Scholar
  38. [41]41. Robert, C. ∙ Long, G.V. ∙ Brady, B. ... Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med. 2015; 372:320-330 Crossref Scopus (4541) PubMed Google Scholar
  39. [43]43. Tran, E. ∙ Turcotte, S. ∙ Gros, A. ... Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer Science. 2014; 344:641-645 Crossref Scopus (1351) PubMed Google Scholar
  40. [44]44. Roche, P.A. ∙ Furuta, K. The ins and outs of MHC class II-mediated antigen processing and presentation Nat Rev Immunol. 2015; 15:203-216 Crossref Scopus (687) PubMed Google Scholar
  41. [45]45. Loos, M. ∙ Giese, N.A. ∙ Kleeff, J. ... Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer Cancer Lett. 2008; 268:98-109 Full Text Full Text (PDF) Scopus (121) PubMed Google Scholar
  42. [46]46. Hepworth, M.R. ∙ Fung, T.C. ∙ Masur, S.H. ... Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4(+) T cells Science. 2015; 348:1031-1035 Crossref Scopus (401) PubMed Google Scholar
  43. [47]47. Clark, C.E. ∙ Hingorani, S.R. ∙ Mick, R. ... Dynamics of the immune reaction to pancreatic cancer from inception to invasion Cancer Res. 2007; 67:9518-9527 Crossref Scopus (793) PubMed Google Scholar
  44. [48]48. Lutz, E.R. ∙ Wu, A.A. ∙ Bigelow, E. ... Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation Cancer Immunol Res. 2014; 2:616-631 Crossref Scopus (403) PubMed Google Scholar
  45. [49]49. Gaida, M.M. ∙ Welsch, T. ∙ Herpel, E. ... MHC class II expression in pancreatic tumors: a link to intratumoral inflammation Virchows Arch. 2012; 460:47-60 Crossref Scopus (17) Google Scholar Figures (4) Article metrics Related Articles Advertisement Hide CaptionDownloadSee figure in Article Toggle Thumbstrip Figure 1 Figure 2 Figure 3 Figure 4 Download .PPT Home Access for Developing Countries Articles & Issues Articles In Press Current Issue

Cited by

Sorted by citations

Authors
Pham, K., Delitto, D., Knowlton, A. E., Hartlage, E. R., Madhavan, R., Gonzalo, D. H., Thomas, R. M., Behrns, K. E., George, T. J., Hughes, S. J., Wallet, S. M., Liu, C., & Trevino, J. G.
Affiliations
  • University of Florida Health (US)
  • University of Florida (US)
Corresponding author
  • Liu, Chen
  • Trevino, Jose G.
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2016-06
Volume
186
Issue
6
Pages
1537-1546
ISSN
0002-9440 (ISSN-L)
OpenAlex
W2337584911
Cited by
46
References
4
Citations by year
2026: 2 · 2025: 3 · 2024: 11 · 2023: 1 · 2022: 5 · 2021: 1 · 2020: 7 · 2019: 8 · 2018: 2 · 2017: 5 · 2016: 1
FWCI
2.88
Type
journal article
Language
en
Open access
Locations
  • American Journal Of Pathology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (5T32CA106493-09)
  • Cracchiolo Foundation (UF115477)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
Keywords
pancreatic cancer, patient-derived xenografts, tumor cell isolation, intratumoral heterogeneity, cancer stem cells, CD44, CD133, c-Met, PD-L1, HLA class I, EpCAM, cytokeratin 19, tumorigenicity
MeSH terms
Aged, Animals, Female, Flow Cytometry, Fluorescent Antibody Technique, Humans, Male, Middle Aged, Pancreatic Neoplasms, Phenotype, Cell Culture Techniques, Cell Line, Tumor, Mice, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review